Jake Shortt
The University of Melbourne(AU)Peter MacCallum Cancer Centre(AU)Monash Health(AU)Australasian Leukaemia and Lymphoma Group(AU)Monash University(AU)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, Histone Deacetylase Inhibitors Research, Multiple Myeloma Research and Treatments
Most-Cited Works
- → BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1(2017)296 cited
- → Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy(2012)207 cited
- → Oncogenes in Cell Survival and Cell Death(2012)192 cited
- → Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition(2021)160 cited
- → Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial(2023)159 cited
- → CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo